Xilio Therapeutics Inc XLO 深 滬
已收盤 02-06 16:00:00 美东时间
0.5409
+0.021
+4.04%
華盛通- 最 高0.5483
- 今 開0.52
- 成交量 45.44万股
- 最 低 0.51
- 昨 收 0.5199
- 總市值 3653.29万
- 52周最高 1.215
- 市盈率 靜 --
- 換手率 0.67%
- 52周最低 0.5095
- 委 比 -75.68%
- 總股本 6754.09万
- 歷史最高 27.95
- 量 比 0.77
- 振 幅 7.37%
- 歷史最低 0.49
- 每 手 1
- 風險率 0.11%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Xilio Therapeutics Q3 EPS $(0.11) Misses $(0.03) Estimate, Sales $19.066M Beat $18.635M Estimate
Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.03) by 266.67 percent. This is a 50 percent increase over losses of $(0.22) per share from
2025-11-13 20:37
Xilio Therapeutics Presents New Data Across Portfolio, Including Preclinical Data Highlighting Potential For Masked T Cell Engager Platform And Programs, As Well As Phase 1 Data For Efarindodekin Alfa, And Phase 2 Data Related To Ctdna For Vilastobart, At SITC 2025
Preclinical data support best-in-class potential of masked T cell engager programs and platform utilizing Xilio's ATACR and SEECR formats, including efficient masking, potent anti-tumor activity and broad therapeutic
2025-11-07 22:14
Xilio Therapeutics Announces It Will Present Late-Breaking Phase 2 Data For Vilastobart At The SITC 40th Annual Meeting Nov 5–9, 2025
Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it will present a
2025-10-30 21:05
Xilio Therapeutics Transfers Listing to Nasdaq Capital Market
Xilio Therapeutics ( ($XLO) ) just unveiled an update. On October 2, 2025, Xili...
2025-10-03 19:58
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
Xilio Therapeutics将在2025年11月6日至9日举行的SITC年会上展示其肿瘤激活免疫疗法的最新数据，包括vilastobart和XTX301的临床数据，以及T细胞衔接器的临床前研究。主要展示内容包括微卫星稳定的转移性结直肠癌患者的ctDNA作为潜在生物标志物、XTX301的药代动力学数据，以及新型T细胞衔接器的设计概念，均在Gaylord会展中心展出。
2025-10-03 13:00
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xilio Therapeutics granted 26,000 non-qualified stock options to three new employees under its 2022 Inducement Stock Incentive Plan effective October 1, 2025. The options have an exercise price of $0.8326 per share, equal to the closing price on October 1, 2025, and a ten-year term. They vest 25% upon the first anniversary of employment, with the remaining 75% vesting in 36 monthly installments. Xilio Therapeutics is a clinical-stage biotech comp...
2025-10-02 20:30
Xilio Therapeutics Initiates Patient Dosing In Phase 2 Of An Ongoing Phase 1/2 Clinical Trial Evaluating Efarindodekin Alfa As Monotherapy In Patients With Certain Advanced Solid Tumors
Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumorsAchievement of milestone extends anticipated cash runway into first quarter of
2025-09-09 19:37
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead
Xilio Therapeutics announced the initiation of Phase 2 for efarindodekin alfa (XTX301), a tumor-activated IL-12, in patients with advanced solid tumors, following promising Phase 1 data showing two partial responses and a generally well-tolerated safety profile. The company also achieved a $17.5 million development milestone under its license agreement with Gilead Sciences, extending its cash runway into the first quarter of 2027. Efarindodekin a...
2025-09-09 11:30
Xilio Therapeutics Q2 EPS $(0.16) Misses $(0.08) Estimate, Sales $8.084M Miss $8.210M Estimate
Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.08) by 100 percent. This is a 33.33 percent increase over losses of $(0.24) per share from
2025-08-14 19:33
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors
Xilio Therapeutics announced the appointment of Dr. Akintunde (Tunde) Bello to its board of directors. With over 25 years of experience in oncology research and development, Dr. Bello has successfully developed novel therapies, including cancer immunotherapies like anti-CTLA-4, PD-1, and T-cell engagers. His expertise will support Xilio’s clinical advancements, particularly with its masked PD-1/IL-2 bi-specific, XTX501, and its T-cell engager pro...
2025-06-10 20:30
